Actively Recruiting

Phase Not Applicable
Age: 35Years - 65Years
All Genders
ID07123987

Transcutaneous Auricular Vagus Nerve Stimulation as an Adjunct Therapy for Post-Herpetic Neuralgia

Led by Mohamed Hosny Ismail Easa · Updated on 2026-03-18

34

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Post-herpetic neuralgia (PHN) is a long-lasting nerve pain that occurs after shingles (herpes zoster) infection. This study investigates whether adding transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive nerve stimulation technique, to standard treatment can reduce pain and improve quality of life for people aged 35 to 65 with PHN. The trial includes both men and women and compares the effects of taVNS plus usual care to usual care alone. Participants are divided into two groups: one receives taVNS using the EV-906 device with TENS ear clips alongside their regular medical treatment, and the other receives only the regular medical treatment. The stimulation is applied according to safety standards and study protocols. The study runs for four weeks with assessments at the start, after two weeks, and after four weeks to measure changes in pain intensity and how pain affects daily activities. During the study, participants will undergo interviews using the Brief Pain Inventory short form and the Short-form McGill Pain Questionnaire-2 to evaluate pain severity and interference. Researchers will monitor pain levels and quality of life throughout the trial. The goal is to see if taVNS can be a safe, non-invasive addition to current therapies for managing PHN. The study lasts about one month for each participant, with close attention to safety and treatment effects.

CONDITIONS

Brief Title

Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia

Who Can Participate

Age: 35Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 35 to 65 years diagnosed with post-herpetic neuralgia
  • Persistent pain for at least 3 months after herpes zoster infection
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Presence of active implants such as pacemakers, cochlear implants, or brain shunts
  • Previous neurological or psychiatric diagnoses
  • History of addiction or substance abuse
  • History of trauma or brain surgery
  • Cardiac disease
  • Acute or chronic use of medications or illicit drugs
  • Susceptibility to headaches and seizures
  • Severe cognitive impairment
  • Other chronic pain conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 weeks

Participants receive either transcutaneous auricular vagus nerve stimulation (taVNS) along with standard medical treatment or standard medical treatment alone for post-herpetic neuralgia.

3 visits (baseline, 2 weeks, and 4 weeks; in-person interviews for pain assessments)

Trial Site Locations

Total: 1 location

1

Faculty of Physical Therapy - Cairo University

Cairo, Giza Governorate, Egypt, 12613

Actively Recruiting

Loading map...

Research Team

M

Mohamed Hosny Ismail Easa, MSc, PT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Comparative Efficacy of Pregabalin and Lacosamide in Patient...

Herpes Zoster (HZ)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here